AN INTRODUCTION TO NIRSEVIMAB

Ivana Kalanovic Dylag; Andrew Dylag

doi:10.46793/PP240220001K

Authors

Ivana Kalanovic Dylag University of Rochester School of Medicine Rochester, New York
Andrew Dylag Department of Pediatrics, Division of Neonatology University of Rochester School of Medicine, Rochester, New York

DOI:

https://doi.org/10.46793/PP240220001K

Keywords:

Nirsevimab, respiratory syncytial virus, respiratory infection

Abstract

Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide. It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness. Due to this high disease burden, the development of new agents to prevent or reduce the spread of RSV has been a top priority. Recently, nirsevimab, a new monoclonal antibody was introduced for the 2023-2024 winter season that holds promise for limiting the spread, morbidity, and mortality associated with RSV.

References

Meissner, H.Cody. “The Beginning of a New Era in RSV Control.” Pediatrics. Volume 152. Number 5. Pages: 52-55. November 2023.

Sun, Mingyao,et al. “Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children. A Systematic Review and Network Meta-analysis.” JAMA Network. 6(2). February 17, 2023.

“Respiratory syncytial virus infection: Prevention in infants and children.” www.uptodate.com. Accessed: February 18, 2024.